PLoS medicine, 2019-07, Vol.16 (7), p.e1002851-e1002851
2019
Details
- Autor(en) / Beteiligte
- Titel
- Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
- Ist Teil von
- PLoS medicine, 2019-07, Vol.16 (7), p.e1002851-e1002851
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1549-1676, 1549-1277eISSN: 1549-1676DOI: 10.1371/journal.pmed.1002851Titel-ID: cdi_plos_journals_2314539215
- Format
- –
- Schlagworte
- Abbreviations, Antitubercular agents, Antitubercular Agents - adverse effects, Antitubercular Agents - pharmacokinetics, Antitubercular Agents - therapeutic use, Bactericidal activity, Bedaquiline, Biological markers, Biology and Life Sciences, Biomarkers, Clinical trials, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Collection Review, Combination drug therapy, Computed tomography, Critical path, Drug development, Drug Development - trends, Drug dosages, Drug interaction, Drug interactions, Drug therapy, Drug Therapy, Combination, Emissions, Humans, Infectious diseases, Liquid culture, Medical innovations, Medicine and Health Sciences, New technology, Patient Safety, Patients, Pharmacodynamics, Positron emission, Positron emission tomography, Product development, Research and analysis methods, Research Design - trends, Rifampin, Rifamycins, Rifapentine, Risk Assessment, Risk Factors, Risk management, Risk reduction, Studies, Technology, Testing, Tomography, Treatment Outcome, Tuberculosis, Tuberculosis - diagnosis, Tuberculosis - drug therapy, Tuberculosis - microbiology, Workflow